How to Cite:
Arora, S., Kumar, D., Akram, W., Alam, S., Bhati, K., Kumari, A., & Sharma, V. (2022). Novel treatment strategies and involvement of international agencies for the control of asthma. *International Journal of Health Sciences*, *6*(S1), 11025–11050. https://doi.org/10.53730/ijhs.v6nS1.7651

Novel treatment strategies and involvement of international agencies for the control of asthma

Swamita Arora
Department of Pharmacology, R. V Northland Institute of Pharmacy, Dadri, U.P.-203207, India,
Corresponding Author Email: arora.swamita@gmail.com

Devesh Kumar
Department of Pharmacology, R. V Northland Institute of Pharmacy, Dadri, U.P.-203207, India.

Wasim Akram
Department of Pharmacology, R. V Northland Institute of Pharmacy, Dadri, U.P.-203207, India.

Sanjar Alam
Department of Pharmacology, R. V Northland Institute of Pharmacy, Dadri, U.P.-203207, India.

Kanchan Bhati
Department of Pharmacology, R. V Northland Institute of Pharmacy, Dadri, U.P.-203207, India.

Akancha Kumari
Department of Pharmacology, R. V Northland Institute of Pharmacy, Dadri, U.P.-203207, India.

Vikash Sharma
Department of Pharmacology, R. V Northland Institute of Pharmacy, Dadri, U.P.-203207, India.

Abstract---Background: Asthma is a chronic airway inflammatory disease, in which the excessive mucus adheres to the airway tube and causes narrowing of the respiration tube which is responsible for the difficulty in breathing. Around 235 million persons are affected with severe asthma worldwide. Purpose: The purpose of this study is to investigate and review the mechanisms of treatment strategies for asthma and the benefits or complications of nutrition supplements

International Journal of Health Sciences ISSN 2550-6978 E-ISSN 2550-696X © 2022.
Manuscript submitted: 27 March 2022, Manuscript revised: 18 April 2022, Accepted for publication: 9 May 2022

used in asthma, and the role of international agencies which stands for the treatment and management of asthma. Method: We search the randomized clinical trial, case reports, clinical studies, and preclinical studies with the use of search keys like asthma exacerbation, treatment strategies involve in asthma, Preclinical studies of asthma, supplement support or management of asthma, etc. we search the total 311 studies and based upon the inclusion criteria total 123 studies are included. Conclusion: According to the findings corticosteroids and Leukotrienes are mainly used for the treatment of early stages of asthma, for severe inflammation, the add-on therapy for corticosteroids with SABA and LABA may effective. Some biological compounds like Omalizumab, Reslizumab, and Benralizumab are used to treat asthma. For better results, natural therapies and nutrition supplements like Co-Q10, vitamins, Pycnogenol &, etc are used to minimize the asthmatic condition. Sometimes that supplement shows an adverse effect on the patient's health like; diarrhea, nausea, and heartburn with Co-Q10 and Pycnogenol cause side effects such as mouth ulcers, urinary problems, gastrointestinal ulcers, dizziness, vertigo, and Cumin over consumption cause heavy bleeding during menstruation cycle, anaphylaxis, drowsiness, etc.

Keywords---Asthma, Exacerbation, Coenzyme Q10, ICS, SABA, LABA, Natural therapies, Treatment strategies, Allergic rhinitis.

Abbreviations

APCs - Antigen-presenting cells,
BALF - Bronchoalveolar lavage fluid,
CD14 - Cluster of differentiation 14,
COPD - Chronic obstructive pulmonary disease,
Th1 - T helper type 1,
Th2 - T helper type 2,
TLRs - Toll-like receptors,
TNF-α - Tumor narcosis factor,
HDM - House dust mite,
ICS - Inhaled corticosteroids,
IFN - Interferon,
IgE - Immunoglobulin E,
IL - Interleukins,
LABA - Long-acting beta antagonist,
LPS - Lipopolysaccharides,
LTs - Leukotrienes,
MD-2 - Myeloid differentiation,
NF-kB - Nuclear factor-kappa B,
PAMPs - Pathogen-associated molecular patterns,
PRRs - Pattern recognition receptors,
RSV - Respiratory syncytial virus,
RVs - Rhinoviruses,
SABA - Short-acting beta 2 antagonists

Introduction

Asthma is a chronic sickness that affects the lungs. Infection is linked to hyperresponsiveness (an exaggerated nasal passages response to various stimuli like viruses, allergens, and exercise), which causes recurrent episodes of gasping for breath, breathing difficulty, tightness of the chest, or coughing that can vary in frequency and intensity over time. Symptom bouts are suddenly conveyed by heavily but varied wind tube blockage in the lungs, which is reversible either freely or with appropriate asthma medication, with that quick bronchodilator[1].
For different patients, asthma is nonstop distress. Others might encounter a major issue that precludes the patients from completing their regular routines and may try and result in a perilous intense sickness. While asthma is hopeless, the side effects can be made due. Even though side effects of asthma could vacillate over the long haul, it's vital to keep a cautious eye on your clinical signs with the doctor and change your treatment on a case-by-case basis. Despite high drug use, 10%-15% of individuals with asthma have lung issues and critical neglected clinical prerequisites, with side effects like horrendous dyspnea, rehashed intensifications, and higher clinic confirmations[2]. The key ecological components ensnared in asthma pathogenic instruments incorporate refinement to allergens, soil, and diet. These antigens are recognized by pole cells covered with IgE antibodies and prompt T lymphocytes as well as eosinophils to produce emission of interleukins IL-5, IL-3, and IL-2, including cytokines growth rot factor (TNF), GM-CSF, receptor, prostaglandins, and leukotrienes (3, 4). Exudate and edema emerge because of this degranulation instrument, which increments vascular penetrability[3]. The indications of asthma differ in person. it appears to have a couple of respiratory issues, and has side effects right at specific times of every day, including while working or feeling unwell constantly. Clinical signs and pointers incorporate Breathing challenges, chest torments, or inconvenience Breathing shallowly and wheezing are typical asthma side effects in adolescents. Resting may be troublesome assuming you have respiratory pain, hacking, or wheezing. A respiratory sickness, including influenza or a cold, can strengthen hacking or wheezing episodes, and the accompanying side effects demonstrate that your asthma is probably going to deteriorate: A contraption that investigations how your lungs perform are utilized to survey the clinical indications of asthma which are more predominant and troublesome[4].

Asthma exacerbation

Intensifications of aviation routes are set apart by bronchospasm, throat aggravation, and bodily fluid creation in association with a trigger one such as an allergen, viral contamination, outer improvements (like residue and smoking cigarettes), or a combo of these. Regardless of the way that ongoing asthma control predicts future intensifications[5], anyway, if you give off an impression of being in finished control and having a satisfactory lung limit, they can happen. Even though regular intensifications and crucial guidelines are tantamount thoughts, truly aren't indistinguishable[6]. Without a doubt, the marks 'compounding' and 'balloon' don't accurately catch the gamble of unexpected cardiovascular and earnestness of these occasions, and 'intensifications' or 'serious lung assault' have now been suggested as better other options[7]. Over portion of asthmatic youngsters inside the United States had a sensitivity assault

every year, as well as more than one among kids in a European examination, had a spontaneous medical services visit attributable to asthma worsening in the past a year[8]. Youngsters with asthma have an extreme disease, including missed school days, hospitalizations, negative medication aftereffects, and a decrease in lung work[9], as well as, in specific circumstances, demise Poor location of misfortunes in youngsters and youth was uncovered to be a vital preventable variable in the late Concluded Review of Asthma Mortality. Asthma assaults and their connected mortality can be abstained from by perceiving these possibly destructive outcomes, screening kids in danger like assault, and further developing expectation models[10].

Bacterial asthma

In typical individuals with persistent asthma, defilement with the abnormal microorganisms Chlamydophila pneumonia and Mycoplasma pneumonia has emerged as a critical clinical concern. While the specific capacity of uncommon bacterial diseases in asthma beginning and aggregate is obscure, a developing assemblage of essential and clinical exploration alludes to these microorganisms as potential asthma benefactors. Through a distal organelle, Mycoplasma pneumonia attacks covered with small aviation route epithelial cells, setting off epithelial apoptosis and ciliary brokenness. M. pneumonia has been connected to new-beginning wheeze, intensifications of existing asthma, and extensive lung work decline recommended job in asthma. Chlamydophila pneumonia support in the development of reactive airway disease and asthma has been linked to Chlamydia pneumoniae respiratory tract infection. In asthma patients, endogenous cytokines pathways that defend from infection with intracellular microorganisms may be disrupted. Mycoplasma pneumonia targets little airplane course epithelial cells through a far-off organelle, causing epithelial demise and ciliary breakage. M. pneumonia has been connected to new-beginning wheeze, escalations of present asthma, and huge lung work decrease, making the occupation in asthma suggested[11].

Viral asthma

Wheezing diseases in children of all ages are connected to viral infections. The major cause of bronchiolitis is a respiratory syncytial virus (RSV), but rhinovirus (RV) is often seen in wheezing kids following that. Severe respiratory disease caused by any of such viruses is linked to induced asthma, with the risk being highest in adults and children who suffer wheezing as a result of RV infections. The question of whether viral diseases cause asthma is hotly debated. RSV-induced wheezing disorders in children have a long-term impact on respiratory health. RSV-induced bronchiolitis has been shown to damage the wind tube, leading to airway blockage and persistent wheezing. Virus infections are connected to wheezing sickness in children of all ages. RSV is the most common cause of bronchiolitis, although RV is the most common cause of wheezing in children. The development of asthma is connected to severe respiratory sickness caused by any of these viruses, with the risk being highest in young children who suffer as a result of RV infections. The argument over whether viral infections cause asthma is raging. Wheezing problems caused by RSV in youngsters have a long-term effect on respiratory health. The airways have been demonstrated to be

damaged by RSV-induced bronchiolitis, resulting in airway obstruction and chronic wheezing. Developing a better knowledge of the environmental and personal variables that encourage more serious viral diseases might lead to novel techniques for preventing viral wheezing infections and possibly lower the chance of developing asthma as a result[12]. *Rhino-Virus (Rvs)* mainly have positive-strand RNA molecules that are not encapsulated and belong to the *Picornaviridae* family and the class Enterovirus. which are divided into three groups (RV-A, RV-B, and RV-C)[13]. There are around 160 particular RV genotypes, with 80 RV-An and 32 RVB serotypes, as well as 65 RV-C serotypes that have only recently been discovered. Antiviral modification has been hanged by the structural and genetic diversity of RV. Because of variations in capsid structure, tiny compounds ("capsid binding agents") that block RV-A and RV-B attached and synchronization are ineffective against RV-C[14]. In vitro, 3C protease inhibitors are efficient, but clinical studies have had mixed outcomes. [15, 16]. Although modern techniques have revealed some potential for cross-breeding among RV types22, and a highly diversified RV vaccine for immune response in experimental animals, the vast quantity of antigenically different RV types has posed a challenge to vaccine development[17].

International Agencies involve Management in Asthma
GINA

The initial GINA report, published in 1995, was entitled "Global Strategy for Asthma Control and Treatment: NHLBI/WHO Workshop Report[18]. Agreeing the GINA study's significant objectives were, nevertheless are, to raise asthma acknowledgment, advance a common sense of the instruments of asthma, its suggestions, and information-based methods for its appraisal and treatment, and feature information holes to prod research. Upgrading asthma treatment and expanding the openness and accessibility of asthma medication, ought to help to decrease asthma entanglement and passing. A Compact Guidance for Medical Practitioners, a Patient Guide, an Advisor for Health Officials, and a preparation slide set were ready by GINA as friend materials. At first, the NHLBI distributed and flowed these distributions, with a few renditions created and scattered across the world. GINA's initial movement was constrained by an Executive Council that gathered one time per year, however in mid-2000, the Executive Council broke up, In light of quick-moving comprehension concerning asthma and its consideration, a Science Committee was made to gather the first 's results of the 1995 report. Besides, a strategy was laid out to help a more standard assessment of distributed research to guarantee that key logically genuine and clinically applicable creating data was engaged with the GINA proclamation on time. GINA's successive investigation of companion evaluated information illuminates customary updates (notwithstanding huge changes framed underneath) and is a separating component of GINA's strategy differentiated to reports and principles distributed through different gatherings, which are for the most part revised just every at least 5 years. The GINA Report has gone through significant changes. They were delivered in 2002, 2006, then, at that point, in 2014, giving new material as well as returning to the general administration of asthma in the light of late advancements in how we might interpret the condition. Reports are accessible on the GINA site (www.ginasthma.org), as are learning diary articles portraying the new or changed ideas inside each version. Yearly updates are

likewise produced and transferred on the GINA page every year, for the most part in January or February[19-21].

Centers for Disease Control and Prevention (CDC)

The CDC has reliably been a pioneer in laying out and breaking down the study of disease transmission and worldwide wellbeing ramifications of helpful calamities, especially complex crises. The CDC's association in CEs started in 1968, when the workforce announced the extent of intense unhealthiness in West Africa, Biafra, because of tactical struggle starvation[22]. The CDC's evaluation of the well-being results of the 1970 Bangladesh storm created epidemiologic methodologies in cataclysmic event-related philanthropic disasters [23]. From 1979 to 1980, the CDC created an aggregation of illness anticipation and dynamic observation programs used by Khmer outcasts over Kampuchea (Cambodia) in Thailand, followed by an abstract of gained data concerning general wellbeing worries in CEs. In 1990, Toole and Waldman delivered a report on death rates across dislodged individuals, which spearheaded something like unrefined death rate (CMR) rules to portray CEs genuinely. They became one of the main CDC representatives focused on exploring the study of disease transmission of CEs[24]. In 1994, individuals from the CDC's Goma Epidemiological Group performed a quick bunch concentrate on example examinations in Goma, Zaire (presently the Democratic Republic of the Congo), to report an uncommon demise rate among Rwandan exiles) [25]. Following a careful assessment of dietary studies directed in Somalia in any event, during the starvation of 1991-1992, CDC specialists made ideas for normalizing healthful assessments in CEs. In 1989, Toole et al. delivered a paper on measles control in exile settings, zeroing in on how measles preventive measures during CEs shift from those in ordinary settings[26]. CDC officials addressed the incidence of chronic illnesses in CEs in the 1990s & 2000s[27]has observed negative mental healthcare and social effects in refugees and CE-affected groups [28]Later on, including local and worldwide philanthropic specialists. Through the progression of epidemiologic procedures, creating public limits, further developing reconnaissance, and assessing mediations, the CDC attempts to meet the specific parts of philanthropic circumstances in its endeavors as a whole[29-32].

National Heart, Lung, and Blood Institute (NHLBI)

The NHLBI laid out the NAEPP drive in 1989 to target asthma hardships inside the United States. To limit the asthma-related pervasiveness of ongoing work on the way of life of individuals with asthma, the NAEPP helps in advancing mindfulness and ensuring legitimate findings and care. In 1991, the NAEPP delivered the very first EPR on the evaluation and treatment of asthma. EPR-2, a total update, was delivered in 1997, upheld by an overhaul of chosen subjects in 2002, and lastly, EPR-3, a third release, in 2007. The NHLBI Advisory Council's Asthma professional Working Group closed an appraisal about the need to refresh NAEPP in 2014, Warning Group Report-3: Asthma Detection and Practice Standards (EPR-3), and the substance of such an alteration The NHLBAC Asthma professional Working Group (the elaborate members of the EPR-3 warning gathering) concluded that a designated redesign on six need topics was expected after a talk and assessment of replies to a worldwide call for input about the

requirement for more and likely satisfied of an update. The NHLBAC Asthma Specialist Review Panel chose the fundamental inquiries to respond to in the distributed investigations for every one of the six public needs. The NHLBAC working gathering characterized the patient base, intercession, proper comparators, and related results for each key theme[33].

U.S. Environmental Protection Agency (EPA)

They coordinated the Environmental Quality Index (EQI), a measurement from the US EPA, to the Truven Health Real economy Scan Commercial Statements and Encounters Data to examine the association between air quality and asthma occurrences (hereinafter, Market Scan). The EQI joins information from an assortment of variables across chosen natural regions to give a more far-reaching thought of ailment and superior information on its impact on well-being results T EQI has recently been used in examinations of endurance rates, for example, malignant growth rates, pediatric numerous sclerosis, mortality, and preterm conveyance, and it very well may be advantageous in better figuring out asthma. The Marketplace Scan information base is an authoritative wellspring of private inclusion prescription orders at the singular scale. Subsequently, Market Scan remembers data for millions additional people than a review would, and it isn't powerless to a similar memory or non-reaction one-sided that self-detailed interviews experience the ill effects of. We examine the connection between specific ecological classifications (water, air, land, built, and socio-segment settings) and asthma commonness among U.S. individuals with health care coverage plans gathered in Market Scan. We additionally examine fluctuation by region level agrarian region status since risk factor profiles contrast with normal among metropolitan and provincial areas in the United States, and because asthma research has yielded conflicting outcomes while thinking about country metropolitan changes.[34].

American Academy of Allergy Asthma & Immunology (AAAAI)

The AAAAI is committed to further developing hypersensitivity, asthma, and immune care information and practice for better understanding consideration. The AAAI developed from two expert associations established in the mid-1920s: the Academy for the Investigation of Asthma and Related Problems (on the East Coast) and the American Association for the Advancement of Allergy (on the West Coast) (on the West Coast). In 1943, these two associations converged to turn into the American Academy of Allergy, a more grounded, more joined proficient body. Notwithstanding the name change, the Academy's goal continues as before: to improve sensitivity, asthma, and immunology data for better quiet treatment. New practice proposals should be firmly analyzed by many gatherings of trained professionals, including specialists and immunologists, pediatricians, and children, specific once they are radically not quite the same as past methodologies. Observing permits for the estimation of acknowledgment pervasiveness, yet additionally for the appraisal of execution jumps that can prompt explicit investigations and vocation rule changes. The aftereffects of a study attempted in association with AAAI to appraise suggestions consistency among allergists and clinical analysts who offer food sensitivity administrations to infants matured a year in the United States are introduced. Rules data, food

sensitivity programs for babies, commonality and certainty, obstacles to and concerns concerning Guideline consistency, references for Rules and norms assessments, and prerequisites for Guidelines preparing and practice help were additionally evaluated[35].

American Academy of Family Physicians (AAFP)

The AAFP has delivered new materials to help with the conclusion of ongoing obstructive pneumonic sickness (COPD) and asthma, as well as tolerant self-administration. In patients' year and a half to mature 18 who showed up to the earnest consideration with extreme asthma intensifications, treatment with injectable magnesium sulfate diminished the dangers of hospitalizations by 68% (N = 115; chances proportion [OR] = 0.32; 95% certainty limit [CI], 0.14 to 0.74). If nasal corticosteroids and short-term working bronchodilators were effected less, Magnesium sulfate was utilized assuming that breathing in short-term working bronchodilators and corticosteroids was fruitless. Even though measurements were not normalized, most preliminaries utilized the British National Drug plan for Children's proposals of 40 mg for each kg of weight up to the greatest portion of 2 g managed as a one iv trickle north of 20 minutes. Because of the undeniable amount and size of examinations, the appraisal was restricted, even though there are no reports of injury. Patients were not isolated into bunches relying upon the seriousness of their asthma, for example, the Juvenile Asthma Total Score or the Juvenile Respiratory Diagnostic Measure[36].

American Lung Association (ALA)

Clinical exploration depends intensely on certifiable informed assent. Informed assent involves enlightening the individual concerning the goal of the exploration, any tests or tasks that might be incorporated, their inclinations, and the potential dangers and benefits of association. To meet administrative standards, informed assent arrangements have developed lengthier and more required throughout the long term. This endangers members' understanding and the proclamation's planned reason. Somewhere in the range between 2000 and 2015, we inspected the trouble of informed assent papers in eight ALA Asthma Clinical Research Center clinical examinations. The volume of material has developed over the long haul, and the openness was at a college level, the two of which outperform contemporary accepted procedures. More limited authorization structures and the utilization of innovation leap forwards (general media) show potential [37].

Asthma and Allergy Foundation of America (AAFA)

The CDCP keeps on ordering moderate-to-extreme asthma as a respiratory sickness that can expand your gamble of COVID-19-related ailment. Even though asthmatics are not the most serious gamble for COVID-19, holding your asthmatic underline is fundamental. Coronavirus isn't expanded by taking normal asthma and sensitivity prescriptions. They will help you in dealing with your asthma. Assuming you quit consuming your asthma drugs, you're bound to have an asthma assault. Accept your prescriptions as coordinated in your Asthma Implementation Plan at the main sign of side effects. Keep on accepting your drugs as coordinated. Effective drugs (like albuterol), Corticosteroids breathed in

(regulator prescriptions), Corticosteroids utilized orally (like prednisone), Biologics Antihistamines are meds that are utilized to treat sensitivities (anti-histamine) Acid reflux meds, nasal sensitivity splashes, and sensitivity infusions[38].

Asthma Disparities Work Group

Despite significant progressions in asthma treatment for kids, there are still variations in results. An Asthma Inequalities Working Group was shaped by the President's Response Team on Ecosystem Health Effects and Child Hazardous Conditions to fit data and government drives connected with asthma errors. The National Institutes of Health (NIH) gave two supporting choices in December 2014 to elevate application studies to grasp these inconsistencies. The first was each U34 technique to survey public requirements, layout, and ACIP, and recommend a clinical test to inspect the ACIP. The second was for sure a six-year execution and assessment system for the ACIPs. To oversee asthma in four regions, ACIPs are required: clinical consideration, local area, home, and family[39].

Treatment Strategies

Asthma control medicines lower fiery reactions and help to keep away from asthma assaults; breathed corticosteroids (ICS) are the groundwork of asthma treatment, while speedy alleviation (reliever) or salvage treatments address intense side effects.

The ICS/LABA Strategy to Present Control and Future for Disease Prevention

In patients with asthma who are not well managed on a modest dosage of ICS, there are two options for improving and increasing the ICS with LABA [40]. However, there has been some worry that adding a LABA to a modest dosage of ICS may better present control while masking inflammation, raising the future risk[41, 42]. Formoterol is acceptable for usage in this approach in conjunction with beclomethasone or budesonide as both managed and relief treatments because of its quick onset of action [43, 44]. Various clinical trials and real-world research have looked into budesonide/formoterol sustaining and relief therapy[44-46]. Over 3 hours, it exhibits equal therapeutic effects and safety profile to salbutamol in the treatment of mild bronchial cell constriction in asthma patients; its bronchial cell dilation action is visible one minute after therapy. In one trial, formoterol/beclometasone with salbutamol was shown to be more effective against alone treatment for asthma exacerbations than formoterol/beclometasone plus as-required salbutamol at preventing asthma exacerbations (figure 1) [44, 47].



Figure 1. Mechanism: Breathed in corticosteroid and long-acting β2-agonist guideline of aviation route smooth muscle cell multiplication proposed techniques. (CAMP- cyclic adenosine monophosphate, GC- glucocorticoid, p21Waf1/Cip1, cell cycle inhibitor; PKA- protein kinase A) [48].

ICS Therapy for Persistent Asthma

The Medication for Asthma in babies research (n = 300) was in children aged 12 to 59 months, a multicenter, randomized, twofold visually impaired, twofold faker clinical trial was conducted for, those who needed daily controlling (Step 2) therapy for asthma. Daily inhaled corticosteroids (ICS), daily leukotriene blockers, and as-required ICS treatment significantly exceeded with albuterol were used for a 2- 8 weeks, followed by three crossover intervals with daily ICS, daily leukotriene blockers, and as-required ICS treatment significantly exceeded with albuterol figure 2 [49].



Figure 2. Mechanism: Inhaled corticosteroids minimize inflammation in the airway wall in aviation route epithelial cells, smothering the record of various provocative qualities. INOs represent incited NO synthase; COX-2 addresses for instigated cyclooxygenase; cpla2 addresses for cytosolic phospholipase A2; ET-1 addresses for endothelin-1; and ICAM-1 addresses for intercellular grip atom.

ICS/SABA Therapy as a Reliever in Mild Asthma

The concept that utilizing a relief with both a quick-onset 2-agonist and an ICS would be preferable to using a 2-agonist just as relief was tested in 2007 in individuals who were assessed to have mild asthma at the time[50]. Following a run-in period on moderate dosage ICS, the BEST trial included four treatment arms: as required addition of ICS and SABA (salbutamol) from a single inhalation; as required SABA only; managed ICS with SABA as required, and managed combination ICS/SABA with SABA as required. When compared to required SABA alone, symptom-driven usage of the combination ICS/SABA increased peak flow rates and the forced expired volume per second (FEV1) and minimized exacerbations, but it was not different from the upkeep ICS and managed combination ICS/SABA groups. When compared to the other two ICS-containing treatment groups, the cumulative dosage of ICS in the as-required ICS/SABA group was significantly lower. In the TREXA research, ICS and SABA were administered via different inhalers to kids ages 5 to 18 with moderate asthma, using a comparable design and experimental arms.[51].

Immunotherapy

In a 2017 systematic review, 10 of 18 trials discovered that AIT reduced the emergence of new exposure in allergic mono- or polysensitized individuals, However, a responsiveness study could not confirm this. The authors summarized that there is a poor degree of evidence that AIT can minimize the emergence of new allergy sensitizations[52]. The outcomes of the two RCTs with nonsensitized babies are inconclusive. AIT is a therapy that can alter the course of a disease. tolerance-inducing cells, Specific blocking antibodies, and mediators are triggered by injecting allergen extracts. These suppress the particular immune response and reduce the inflammatory reaction in the tissue, preventing further severity of the allergen-triggered immunological response. AIT with grass, HDM, and the cat did not affect new sensitizations in babies with atopic dermatitis, whereas oral AIT with HDM reduced the likelihood of acquiring any sensitivity to food or antigen in non-sensitized children born to atopic parents (9.0% vs. 26.6%, P.03) (Figure 3) [53].



Figure 3. DC- dendritic cell, IL- interleukins, T reg.- T regulatory cells, IgE- immunoglobin E, igg- immunoglobin G, TNF-α – tumor necrosis factor α, IFN-γ - Interferon-gamma, Th2- T helper type 2.

Leukotriene Treatments

The use of LTRA in the medication of asthma and the mechanisms of its-related allergic asthma. The engagement of its C4/D4/E4 in various features of airway inflammation and remodeling has been established. Recently, novel routes involving LTE4, the most powerful mediator, and its transporters have been discovered. Montelukast, pranlukast, and zafirlukast, agonists against cysltr

(cysteinyl leukotriene receptor) type 1, have been broadly prescribed in clinical practices; however, a few clinical trials have already shown non-significant feedback in independent person asthmatics, whereas some phenotypes of exacerbations, such as aspirin-exacerbated pulmonary illness, elderly asthma, asthma due to obesity, smoking and hypersensitivity reactions [55, 56]. The inhibitory impact of montelukast was drastically reduced when treated with S-hexyl-GSH, however, baycyslt2ra was markedly boosted. In both S-hexyl GSH-non-treated and treated rats, the dual cyclic HT1/2 receptor antagonist successfully suppressed anaphylactic reactions. According to LC/MS/MS analyses, S-hexyl GSH administration reduced LTC4 biotransformation in the erythrocytes and lung tissues. We created a new cyslt1 and cyslt2 receptor-mediated anaphylactic animal model using S-hexyl GSH, which may be used for not only analyzing cyslt2 and cyslt1/2 receptor antagonists but also mean the investigation of cyslt2 receptors (figure 4) [57, 58].



Figure 4. Metabolism of arachidonic acid. Cysteinyl leukotrienes (LTC4, LTD4, LTE4) bind to a particular receptor that can be inhibited with antagonists like montelukast or zafirlukast. HPETE stands for 5-hydroxy peroxy eicosatetraenoic acid, while FLAP stands for 5-lipoxygenase activating protein[59].

Biologic Therapy

Biologic therapy is designed to target distinct inflammatory pathways associated with the pathophysiology of asthma, especially in individuals with a type 2 (T2) endotype. Anti–IL-5 biologics and one anti–IL-4R biologic have been just considered powerful therapies for T2 asthma, in the combination to anti–IgE therapy, which enhanced effects in allergic asthma further than a generation. In suitably chosen individuals, these targeted therapies have been demonstrated to

minimize asthma exacerbations, promote lung function, minimize oral corticosteroid use, and enhance the quality of life. In addition to the biologics that have already been authorized, other biologics that target proximal inflammatory mediators are in clinical studies and might be approved soon (table 1) [60].

Table 1
Biologics used in asthma

S. No.	Therapy	Dose and route	Indication	Mechanism
1.	Omalizumab	0.016 mg/kg per Unit of IgE	Fitting sensitivity separating extreme control including ICS, and IgE: 30-1,300 U/ml (the US, age 6-11 years),	Hostile IgE is an immune response that blocks IgE from appending to its objective on pole cells and basophils.
2.	Mepolizumab	100 mg s.c. Every 4 wk	Other GINA stage 4-5 treatments neglected to assist a 12-year-old with serious eosinophilic asthma. 150-300 cells/l AEC levels are shown.	Anti–IL-5; interacts with the IL-5 ligand and blocks IL-5 from attaching to its target.
3.	Reslizumab	Weight-based dosing of 3 mg/kg i.v. Every 4 wk	Other GINA stage 4-5 treatments neglected to assist a 12-year-old with serious eosinophilic asthma. 150-300 cells/l AEC levels are shown.	Against IL-5 associates to the ligand for IL-5 and prevents it from connecting to its objective.
4.	Benralizumab	30 mg s.c. Every 4 wk for three doses	Other GINA stage 4-5 treatments neglected to assist a 12-year-old with serious eosinophilic asthma. 150-300 cells/l AEC levels are shown.	It joins the IL-5 transmitter and is against IL-5.

Natural Remedies
Medicinal Plant

- **AdhatodaVasica:** At physiological, histological, and molecular levels, we investigated the remedial benefits and pharmacological basis of Adhatodavasica (AV) aqueous extract on animal models of chronic allergic and non-allergic asthma subtypes. In severe asthmatic mice, the oral treatment of AV extract reduces respiration blockage and inflammation in the serious allergic asthmatic model, as well as molecular markers of steroid (dexamethasone) mutation such as KC (murine IL-8 homolog), IL-17A, and HIF-1 (hypoxia-inducible factor-1). HIF-1 levels are inhibited by AV by restoring the expression of downregulation, PHD2. In the mild and severe asthma scenarios, the modulation of hypoxic response facilitated by AV is further demonstrated. In silico docking of AV, components reveal that C and O—glycosides for IL-6, HIF-1, TNF-alpha, Janus kinase 1/3, and TGF-—key factors in hypoxic inflammation—have a greater negative binding affinity[61].
- **Curcuma longa:** When asthmatic mice were given all amounts of C. longa, BALF levels of PLA2 and total WBC, NO2, NO3, and IgE were considerably lower than in the asthmatic model. When compared against the untreated asthmatic model, two higher dosages of C. longa considerably lowered eosinophil and neutrophil counts, as well as MDA levels, IFN-/IL-4 ratio, IL-4, TP but dramatically raised lymphocyte count, and levels of IFN, BALF, CAT, SOD, and thiol[62].
- **Glycyrrhiza glabra**: One of the main causes of asthma is a cytokine called TSLP. Nuclear factor-kappa B regulates the hyperactive expression of TSLP (NF-kb). It was discovered that licochalcone A blocks TNF-induced NF-kB trigger via blocking Ikb kinase complex activity. Several studies have found that licorice flavonoid IgE levels, minimize eosinophilic lung infection, and IL-13, IL-5, and IL-3 levels, as well as increase INF-activity. Several studies investigated the effect of glycyrrhizic acid on asthma, including one on six groups of rats with ovalbumin-induced asthma [control group, model group, dexamethasone (2 mg/kg), glycyrrhizic acid groups 1, 2, and 3 (10, 20, 40 mg/kg)]. the animal groups exposed to glycyrrhizic acid were shown to be significantly stressed, with IL-13, IL-5, IL-4, and IgE levels much higher than the model group[63].

Essential Oils

- **Thyme Oil:** In trials, anti-inflammatory properties were viewed, to reduce the levels of inflammatory biomarkers [64]. As a result, thyme oil therapy is likely to minimize BA exacerbations, reduce the need for steroids, and enhance asthmatic patients' quality of life[65]. Thymus vulgaris contains several phytochemical components such as phenolics, terpenoids, and tannins, with thyme oil being the active element[66]. However, thyme oil's key active constituents (carvacrol, thymol, linalool, and cymene,), which have antibacterial, anti-inflammatory, and antioxidant characteristics are responsible for the majority of its benefits. As a result, by altering inflammatory and apoptotic signaling pathways, thyme oil can help to alleviate chronic inflammatory conditions[67, 68]. Furthermore, decreasing

the expression of nuclear factor-KB, TNF, IL-13, IL-5, and IL-4 can reduce the synthesis of proinflammatory mediators and regulate their release in a variety of disorders [69-71]. Thyme oil reduces the oxidative stress, and apoptotic and inflammatory effects of OVA in G4 rabbits, which might explain the improvement in AWR. Our findings help to explain why thyme oil has immunomodulatory, anti-inflammatory, anti-apoptotic, and antioxidant characteristics and how it may be used to treat a variety of chronic inflammatory illnesses, including BA[72].

- **Eucalyptus Oil:** In alveolar lavage fluid, the higher potency of the medication group shows an inhibitory effect on CD8. In lung fluid, both the low-dose and medium-dose groups demonstrated an up-regulation impact on CD8. Macrophage phagocytosis was affected by the higher potency of the medication group. The intermediate dosage, low dose, and control groups showed no significant differences. The CD4 level in the lungs fluid did not change significantly from the CD4 in the control group, demonstrating that eucalyptol did not affect CD4 in the blood alveolar fluid of rats[73].
- **Peppermint Oil:** Treatment with Mentha essential oil (MEO) resulted in lower levels of IL-6, as well as lower levels of T helper-2-specific cytokines and-inflammatory. MEO substantially reduced PM10-induced phosphorylation of JAK2 and STAT3. In the situation of PM10 exposure, MEO may have to prohibit effectiveness on asthma via the IL-6/JAK2/STAT3 signaling pathway[74]. The necessity of testing with a variety of different measures to particular IgE to mints, such as Mint juice and peppermint leaves were utilized to test the skin, is highlighted in this instance. Furthermore, this instance demonstrates that breathing the aroma of mint can cause asthma, and it advises that confirming pre- and process is identified pulmonary function data be obtained using both impulse oscillometry and spirometry[75, 76].

Coenzyme Q10

Coenzyme Q10, a naturally existing biomolecule with significant anti-inflammatory and antioxidant properties in the mitochondria, is a key part of the mitochondrial electron transport chain. Coq10 is effective in the prevention of asthma in several clinical investigations. Coq10 was administered daily for 15 weeks to asthmatic rats at a dosage of 10 mg/kg p.o. On the other hand, coq10 therapy effectively reduced the chances of inflammatory cells and boosted the differential count to the normal recommended range[77]. The principal function of CoQ10 in the mitochondria is as a crucial intermediary in the electron transport pathway. Cellular respiration and ATP synthesis require sufficient concentrations of CoQ10. CoQ10 impacts the functioning of all cells in the body due to its role in ATP generation, making it necessary for the wellness of all tissues and organs. At the mitochondrial level, CoQ10 also acts as an intercellular antioxidant, which may explain its benefits in neurological disorders and periodontal disease. Coenzyme Q10 is also used as an antioxidant and neuroprotective that functions as an electron adaptive for networks I and II of the mitochondrial charge caring chain. When neuronal cells are exposed to oxidative stress, water-soluble coenzyme Q10 functions by protecting the mitochondrial membrane[78]. Because it can regenerate plasma vitamin E, it would be an excellent plasma antioxidant.

Co-Q10 mode of action

The mechanism of prevention of the asthmatic condition with the supplement of Co-Q10 follows the three pathways (figure 5):

(a) **Mitochondrial respiration:** The mitochondrial oxidative chain catalyzes the oxidation of fuel atoms, moving electrons to sub-atomic oxygen while additionally moving energy to adenosine triphosphate (oxidative phosphorylation)

(b) **Xanthine oxidase immune response:** One more plausible beginning of ROS in vascular turmoil is a xanthine oxidase. Protein delivers the chemical from xanthine dehydrogenase. Xanthine oxidase quickly contributes electrons to sub-atomic oxygen, bringing about the development of oxygen and hydrogen peroxide.

(c) **In coEnvironmental antioxidant defense:** By straightforwardly rummaging ROS or potentially stifling cell development because of protein phosphorylation, cancer prevention agents can lessen prompted oxidative carcinogenesis.



Figure 5. Mechanism of mitochondrial oxidative catalytic pathway in conjunction to xanthine oxidase enzyme dependent depletion of ROS related suppression of inflammation

This investigation corroborated the low antioxidant status previously [79]observed in severe asthma patients. We previously found lower amounts of coq10 and tocopherol in the blood of individuals with steroidal-resistant asthma. [80]. Coq10, a vital component of the mitochondrial airway chain, is an antioxidant that plays a required role in ATP generation. Linnane and Eastwood claim that the fundamental metabolic regulatory role of coq10 in all subcellular membranes

is determined by redox poise variations (in terms of the ratio of minimizing to oxidized form), resulting in a signaling mechanism[81]. Coq10 has a role in molecular bioenergetics, redox balance, metabolic flux control, oxygen radical generation, and gene regulation on a global level. The asthma patients' baseline plasma levels of antioxidant substances, such as coq10 and tocopherol, were both below the guideline range. In the following administration with coq10 as Q-Gel, plasma coq10 levels increased significantly. While there was a drop in plasma MDA levels in group I, this was not the case in the second group, and the reasons for this remain unknown. The most notable finding of this study is that the patients' doses of inhaled corticosteroids were significantly reduced. Coq10 supplementation in rats' results in increased levels in lung tissue and mitochondria, according to our experimental data. As a result, the findings suggest that supplementing with coq10 and other antioxidant nutrients may have a therapeutic advantage in individuals with bronchial asthma[82].

Co-Q10 with two supplementations (O-3 and Mg-S)

Nrf2 is produced in the reaction to allergens, causing mutation in the development of asthma, and playing an important role in lung protection. Co-Q10 boosts Nrf2 expression, and Nrf2 over-stimulation has a significant impact on the regulation of allergic mediators, type 2 cytokines, and inflammatory factors, all of which contribute to the management of allergy and asthma. According to Qixue Du et al., 2021, Co-Q10 with the supplements (O-3 and Mg-S) modulates type 2 cytokines (IL-13, 5, and, 4), EPO, MRC, eosinophilic genes (eotaxin, CCL11, and CCL24), IgE, histamine, BALF eosinophils, peribronchial and perivascular inflammation, Cyc-LT, and LTB4 as main allergic factors (figure 6) [83].



Figure 6. Mechanism of Co-Q10 with O-3 and Mg-S treatment helped Nrf2 articulation, and Nrf2 overexpression regulates type 2 cytokines, allergens, and proinflammatory cytokines and decreases allergic rhinitis.

Future Prospective

Co-Q10 shows a significant role as antioxidant and anti-inflammatory properties clinical as well as preclinical studies, making it useful in the prevention of asthma. Co-Q10 has exerted side effects in gestational women and children, we can overcome this in future if we exert synergistic therapy by administration of Co-Q10 and Nutraceuticals along with vitamins like C, B & B12 which has also important in energy regeneration due to mitochondrial respiration, for the therapeutic control of chronic respiratory infections such as Asthma, COPD and other lungs disorders.

Conclusion

Asthma is a provocative ailment of the aviation routes that go on for a long time. Asthma influences individuals of any age and from varying backgrounds. Notwithstanding, among kids, it is the most continuous ongoing sickness. According to the findings, we conclude the treatment strategies are directed toward the management and cure of asthma. Inhaled corticosteroids are commonly prescribed medicines to minimize asthma symptoms. Add-on therapy, such as corticosteroids with a betanergic drug to mask bronchial inflammation, is sometimes used to treat asthma. Formoterol with beclomethasone is mainly used for ICS with LABA. Treatment with leukotriene may reduce allergic asthma; montelukast, pranlukast, and zafirlukast are potent for allergic rhinitis. Biologic therapy is designed to target distinct inflammation in asthmatic patients. Anti-IL-4R and anti-IL-5 biologic have been considered powerful therapies for T2 asthma. Omalizumab, mepolizumab, and many biologics are used for T2 asthma. In Ayurveda, the ancient natural remedies for asthmatics are used accordingly. Adhatodavasica extract reduces airway resistance and inflammation in serious allergic asthmatics. Curcuma longa considerably suppresses inflammatory cytokine levels, which are responsible for inflammation, one of the main causes of asthma is Glycyrrhiza glabra. It suppresses the thymic stromal lymphopoietin. Many essential oils, like thyme oil, eucalyptus oil, and peppermint oil, may help treat asthma. Co-Q10 was administered to asthmatic individuals for 15 weeks. It shows enzymes generated from xanthine dehydrogenase by proteolysis and shows antioxidant activity. Co-Q10 with two supplementations, Mg-S and O-reduces allergic bio-factors, via Nrf-2 Overexpression, Co-Q10 has a synergistic effect with other vitamins such as vitamin E, vitamin B2, and Co-Q10 with vitamin E may lower the interleukin levels (IL-3, IL-4, and IL-5). Co-Q10 with B2 suggests an anti-inflammatory effect against bronchial inflammation. but it has no clinical evidence for its combined effect. As a result, proper research and investigation are required for its combined effects as well as the mechanism to reduce asthma exacerbation. Co-Q10 appears to have few and modest side effects like diarrhea, nausea, and heartburn. CoQ10 supplements are not suggested for children or pregnant or nursing women due to a lack of survey data. Pycnogenol is used as a supplement for asthma by antagonizing the TLRs. Cumin has been studied for its ability to reduce bronchial irritation and, at times, as an anti-asthmatic agent.

According to our findings, we can control and treat asthma with the proper utilization of Coenzymes along with nutraceuticals and vitamins by exerting synergistic control over the respiratory infection, asthma.

Acknowledgments
We want to acknowledge R. v Northland institute of pharmacy, Dadri, U.P, india for supporting this work.

Conflict of Interest
The authors are having no conflict of interest.

Author Contributions
Swamita Arora, Wasim Akram & Devesh kumar: Conceptualization, Methodolgy.
Devesh kumar, Swamita Arora, Wasim Akram, Vikash Sharma, Kanchan Bhati, Akancha kumari and Sanjar Alam: Writing, Reviewing & editing.
Swamita Arora, Sanjar Alam & Wasim Akram: Supervision.

References

1. K. Vellopoulou, P. Bakakos, Stelios Loukides, Nikos Maniadakis & Georgia Kourlaba.
2. N. Ahmad, R. Ahmad, A. Al-Qudaihi, S.E. Alaseel, I.Z. Fita, M.S. Khalid, F.H. Pottoo, Preparation of a novel curcumin nanoemulsion by ultrasonication and its comparative effects in wound healing and the treatment of inflammation, RSC advances 9(35) (2019) 20192-20206.
3. L. Amaral-Machado, W.N. Oliveira, S.S. Moreira-Oliveira, D.T. Pereira, É.N. Alencar, N. Tsapis, E.S.T. Egito, Use of Natural Products in Asthma Treatment, Evidence-Based Complementary and Alternative Medicine 2020 (2020) 1021258.
4. M. Kraft, The role of bacterial infections in asthma, Clinics in chest medicine 21(2) (2000) 301-313.
5. L. Fleming, Asthma exacerbation prediction: recent insights, Current opinion in allergy and clinical immunology 18(2) (2018) 117-123.
6. (!!! INVALID CITATION !!! (6, 7)).
7. I.D. Pavord, R. Beasley, A. Agusti, G.P. Anderson, E. Bel, G. Brusselle, P. Cullinan, A. Custovic, F.M. Ducharme, J.V. Fahy, U. Frey, P. Gibson, L.G. Heaney, P.G. Holt, M. Humbert, C.M. Lloyd, G. Marks, F.D. Martinez, P.D. Sly, E. von Mutius, S. Wenzel, H.J. Zar, A. Bush, After asthma: redefining airways diseases, Lancet (London, England) 391(10118) (2018) 350-400.
8. K.F. Rabe, P.A. Vermeire, J.B. Soriano, W.C. Maier, Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study, The European respiratory journal 16(5) (2000) 802-7.
9. P.M. O'Byrne, S. Pedersen, C.J. Lamm, W.C. Tan, W.W. Busse, Severe exacerbations and decline in lung function in asthma, American journal of respiratory and critical care medicine 179(1) (2009) 19-24.
10. C. McCaughey, A.P. Watt, K.A. McCaughey, M.A. Feeney, P.V. Coyle, S.N. Christie, Toxoplasma seroprevalance in northern Ireland, Ulster Medical Journal 86(1) (2017) 43-44.

11. e.a. Kraft, The role of bacterial infections in asthma, Clinics in chest medicine 21(2) (2000) 301-313.
12. T. Jartti, J.E. Gern, Role of viral infections in the development and exacerbation of asthma in children, Journal of Allergy and Clinical Immunology 140(4) (2017) 895-906.
13. A. Leino, THE FIRST WHEEZING EPISODE AND THE SUBSEQUENT RISK FOR ASTHMA.
14. L.A. Coleman, S.-K. Khoo, K. Franks, F. Prastanti, P. Le Souëf, Y.V. Karpievitch, I.A. Laing, A. Bosco, Personal Network Inference Unveils Heterogeneous Immune Response Patterns to Viral Infection in Children with Acute Wheezing, Journal of Personalized Medicine 11(12) (2021) 1293.
15. W. Hao, K. Bernard, N. Patel, N. Ulbrandt, H. Feng, C. Svabek, S. Wilson, C. Stracener, K. Wang, J. Suzich, W. Blair, Q. Zhu, Infection and propagation of human rhinovirus C in human airway epithelial cells, Journal of virology 86(24) (2012) 13524-32.
16. F.G. Hayden, R.B. Turner, J.M. Gwaltney, K. Chi-Burris, M. Gersten, P. Hsyu, A.K. Patick, G.J. Smith, 3rd, L.S. Zalman, Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers, Antimicrobial agents and chemotherapy 47(12) (2003) 3907-16.
17. S. Lee, M.T. Nguyen, M.G. Currier, J.B. Jenkins, E.A. Strobert, A.E. Kajon, R. Madan-Lala, Y.A. Bochkov, J.E. Gern, K. Roy, X. Lu, D.D. Erdman, P. Spearman, M.L. Moore, A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques, Nature communications 7 (2016) 12838.
18. N.I.o. Health, L. National Heart, B. Institute, Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLBI, WHO Workshop Report, 1995.
19. N.H. Lung, B. Institute, Global initiative for asthma: NHLBI/WHO workshop report, Global strategy for asthma management and prevention (2008).
20. E.D. Bateman, S.S. Hurd, P.J. Barnes, J. Bousquet, J.M. Drazen, M. FitzGerald, P. Gibson, K. Ohta, P. O'Byrne, S.E. Pedersen, Global strategy for asthma management and prevention: GINA executive summary, European Respiratory Journal 31(1) (2008) 143-178.
21. H.K. Reddel, E.D. Bateman, A. Becker, L.-P. Boulet, A.A. Cruz, J.M. Drazen, T. Haahtela, S.S. Hurd, H. Inoue, J.C. De Jongste, A summary of the new GINA strategy: a roadmap to asthma control, European Respiratory Journal 46(3) (2015) 622-639.
22. C.f.D. Control, Prevention, CDC's 60th anniversary: director's perspective–David J. Sencer, MD, MPH, 1966-1977, MMWR. Morbidity and mortality weekly report 55(27) (2006) 745-749.
23. A. Sommer, W. Mosley, East Bengal cyclone of November, 1970: epidemiological approach to disaster assessment, The Lancet 299(7759) (1972) 1030-1036.
24. M.J. Toole, R.J. Waldman, Prevention of excess mortality in refugee and displaced populations in developing countries, Jama 263(24) (1990) 3296-3302.
25. K. UGANDA, Public health impact of Rwandan refugee crisis: what happened in Goma, Zaire, in July, 1994?, Lancet (London, England) 345 (1995) 339-44.

26. E.K. Noji, M.J. Toole, The historical development of public health responses to disasters, Disasters 21(4) (1997) 366-376.
27. P.B. Spiegel, P. Salama, War and mortality in Kosovo, 1998–99: an epidemiological testimony, The Lancet 355(9222) (2000) 2204-2209.
28. B.L. Cardozo, O.O. Bilukha, C.A.G. Crawford, I. Shaikh, M.I. Wolfe, M.L. Gerber, M. Anderson, Mental health, social functioning, and disability in postwar Afghanistan, Jama 292(5) (2004) 575-584.
29. A. Ager, E. Pasha, G. Yu, T. Duke, C. Eriksson, B.L. Cardozo, Stress, mental health, and burnout in national humanitarian aid workers in Gulu, Northern Uganda, Journal of traumatic stress 25(6) (2012) 713-720.
30. C.B. Eriksson, B. Lopes Cardozo, F. Ghitis, M. Sabin, C. Gotway Crawford, J. Zhu, B. Rijnen, R. Kaiser, Factors associated with adverse mental health outcomes in locally recruited aid workers assisting Iraqi refugees in Jordan, Journal of Aggression, Maltreatment & Trauma 22(6) (2013) 660-680.
31. B. Lopes Cardozo, C. Gotway Crawford, C. Eriksson, J. Zhu, M. Sabin, A. Ager, D. Foy, L. Snider, W. Scholte, R. Kaiser, Psychological distress, depression, anxiety, and burnout among international humanitarian aid workers: a longitudinal study, (2012).
32. A.T. Boyd, S.T. Cookson, M. Anderson, O.O. Bilukha, M. Brennan, T. Handzel, C. Hardy, F. Husain, B.L. Cardozo, C.N. Colorado, Centers for Disease Control and Prevention public health response to humanitarian emergencies, 2007–2016, Emerging infectious diseases 23(Suppl 1) (2017) S196.
33. M. Cloutier, A. Baptist, K. Blake, E. Brooks, T. Bryant-Stephens, E. DiMango, A. Dixon, K. Elward, T. Hartert, J. Krishnan, Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC). 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group, J Allergy Clin Immunol 146(6) (2020) 1217-1270.
34. C.L. Gray, D.T. Lobdell, K.M. Rappazzo, Y. Jian, J.S. Jagai, L.C. Messer, A.P. Patel, S.A. DeFlorio-Barker, C. Lyttle, J. Solway, Associations between environmental quality and adult asthma prevalence in medical claims data, Environmental research 166 (2018) 529-536.
35. J.L. Johnson, R.S. Gupta, L.A. Bilaver, J.W. Hu, J. Martin, J. Jiang, A. Bozen, M.M. Davis, J. Reese, S. Cooper, Implementation of the Addendum Guidelines for Peanut Allergy Prevention by US allergists, a survey conducted by the NIAID, in collaboration with the AAAAI, Journal of Allergy and Clinical Immunology 146(4) (2020) 875-883.
36. B.J. Stojak, E. Halajian, R.A. Guthmann, J. Nashelsky, FPIN's Clinical Inquiries: Intravenous Magnesium Sulfate for Acute Asthma Exacerbations, American family physician 99(2) (2019) 127.
37. J.E. Lang, A. Vadlamudi, Informed consent–current challenges and lessons learned from the American lung association asthma/airways clinical research centers network (ALA-ACRC), Journal of Asthma 56(6) (2019) 581-583.
38. H.C.I.A.G. COVID, Coronavirus (COVID-19): What People With Asthma Need to Know| Asthma and Allergy Foundation of America, Update (2021).
39. M.A. Martin, M.G. Kapheim, K. Erwin, S. Ignoffo, K. McMahon, A. O'Rourke, L.B. Gerald, M. Barrett, V.G. Press, H. Darabi, Childhood asthma disparities

in Chicago: developing approaches to health inequities, Family & community health 41(3) (2018) 135.
40. N.I.o. Health, Global Initiative for Asthma. Global strategy for asthma management and prevention, NHLBI/WHO work shop report (1995).
41. P.M. O'Byrne, I.P. Naya, A. Kallen, D.S. Postma, P.J. Barnes, Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled β2-agonists in achieving asthma control, Chest 134(6) (2008) 1192-1199.
42. B.-J. Lee, Y.-J. Jeung, J.-Y. Lee, M.-J. Oh, D.-C. Choi, Potential masking of airway eosinophilic inflammation by combination therapy in asthma, Allergy, asthma & immunology research 6(2) (2014) 175-178.
43. M. Palmqvist, G. Persson, L. Lazer, J. Rosenborg, P. Larsson, J. Lotvall, Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency, European Respiratory Journal 10(11) (1997) 2484-2489.
44. R. Aalbers, C. Vogelmeier, P. Kuna, Achieving asthma control with ICS/LABA: A review of strategies for asthma management and prevention, Respiratory Medicine 111 (2016) 1-7.
45. B. Stallberg, I. Naya, J. Ekelund, Follow-up programme for patients using Symbicort® Turbuhaler® maintenance and reliever therapy in real-world clinical practice, Prim. Care Respir. J 22 (2013) A11.
46. M. Patel, J. Pilcher, A. Pritchard, K. Perrin, J. Travers, D. Shaw, S. Holt, M. Harwood, P. Black, M. Weatherall, Efficacy and safety of maintenance and reliever combination budesonide–formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial, The Lancet Respiratory Medicine 1(1) (2013) 32-42.
47. A. Papi, M. Corradi, C. Pigeon-Francisco, R. Baronio, Z. Siergiejko, S. Petruzzelli, L.M. Fabbri, K.F. Rabe, Beclometasone–formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial, The Lancet Respiratory Medicine 1(1) (2013) 23-31.
48. M. Tamm, D.H. Richards, B. Beghé, L. Fabbri, Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice, Respiratory medicine 106 (2012) S9-S19.
49. P.J. Barnes, Efficacy of inhaled corticosteroids in asthma, Journal of allergy and clinical immunology 102(4) (1998) 531-538.
50. A. Papi, G.W. Canonica, P. Maestrelli, P. Paggiaro, D. Olivieri, E. Pozzi, N. Crimi, A.M. Vignola, P. Morelli, G. Nicolini, Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma, New England Journal of Medicine 356(20) (2007) 2040-2052.
51. F.D. Martinez, V.M. Chinchilli, W.J. Morgan, S.J. Boehmer, R.F. Lemanske Jr, D.T. Mauger, R.C. Strunk, S.J. Szefler, R.S. Zeiger, L.B. Bacharier, Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial, The Lancet 377(9766) (2011) 650-657.
52. D. Di Bona, A. Plaia, M.S. Leto-Barone, S. La Piana, L. Macchia, G. Di Lorenzo, Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review, Allergy 72(5) (2017) 691-704.

53. J. Gradman, S. Halken, Preventive effect of allergen immunotherapy on asthma and new sensitizations, The Journal of Allergy and Clinical Immunology: In Practice 9(5) (2021) 1813-1817.
54. O. Pfaar, C. Bachert, A. Bufe, R. Buhl, C. Ebner, P. Eng, F. Friedrichs, T. Fuchs, E. Hamelmann, D. Hartwig-Bade, T. Hering, I. Huttegger, K. Jung, L. Klimek, M.V. Kopp, H. Merk, U. Rabe, J. Saloga, P. Schmid-Grendelmeier, A. Schuster, N. Schwerk, H. Sitter, U. Umpfenbach, B. Wedi, S. Wöhrl, M. Worm, J. Kleine-Tebbe, S. Kaul, A. Schwalfenberg, Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD), Allergo journal international 23(8) (2014) 282-319.
55. H.K.T. Trinh, S.-H. Lee, T.B.T. Cao, H.-S. Park, Asthma pharmacotherapy: an update on leukotriene treatments, Expert review of respiratory medicine 13(12) (2019) 1169-1178.
56. H.K.T. Trinh, D.-H. Suh, T.V.T. Nguyen, Y. Choi, H.-S. Park, Y.S. Shin, Characterization of cysteinyl leukotriene-related receptors and their interactions in a mouse model of asthma, Prostaglandins, Leukotrienes and Essential Fatty Acids 141 (2019) 17-23.
57. T. Sekioka, M. Kadode, N. Osakada, M. Fujita, N. Matsumura, Y. Yamaura, S. Nakade, T. Nabe, K. Kawabata, A new CysLT1 and CysLT2 receptors-mediated anaphylaxis guinea pig model, Prostaglandins, Leukotrienes and Essential Fatty Acids 119 (2017) 18-24.
58. T. Sekioka, M. Kadode, M. Fujii, K. Kawabata, T. Abe, M. Horiba, S. Kohno, T. Nabe, Expression of CysLT2 receptors in asthma lung, and their possible role in bronchoconstriction, Allergology International 64(4) (2015) 351-358.
59. O. Dempsey, Leukotriene receptor antagonist therapy, Postgraduate medical journal 76(902) (2000) 767-773.
60. M.C. McGregor, J.G. Krings, P. Nair, M. Castro, Role of biologics in asthma, American journal of respiratory and critical care medicine 199(4) (2019) 433-445.
61. A. Gheware, L. Panda, K. Khanna, N.K. Bhatraju, V. Jain, S. Sagar, M. Kumar, V.P. Singh, S. Kannan, V. Subramanian, M. Mukerji, A. Agrawal, B. Prasher, Adhatoda vasica rescues the hypoxia-dependent severe asthma symptoms and mitochondrial dysfunction, American Journal of Physiology-Lung Cellular and Molecular Physiology 320(5) (2021) L757-L769.
62. M.H. Boskabady, F. Amin, F. Shakeri, The Effect of Curcuma longa on Inflammatory Mediators and Immunological, Oxidant, and Antioxidant Biomarkers in Asthmatic Rats, Evidence-Based Complementary and Alternative Medicine 2021 (2021) 4234326.

63. M.A. Icer, N. Sanlier, N. Şanlier, A review: Pharmacological effects of Licorice (Glycyrrhiza glabra) on human health, International Journal of Basic and Clinical Studies 6(1) (2017) 12-26.
64. D.S. Mendes, M.L. Dantas, J.M. Gomes, W.L.C.d. Santos, A.Q. Silva, L.H. Guimarães, P.R. Machado, E.M.d. Carvalho, S. Arruda, Inflammation in disseminated lesions: an analysis of CD4+, CD20+, CD68+, CD31+ and vW+ cells in non-ulcerated lesions of disseminated leishmaniasis, Memórias do Instituto Oswaldo Cruz 108(1) (2013) 18-22.
65. S. Martín-Peláez, J.I. Mosele, N. Pizarro, M. Farràs, R. De la Torre, I. Subirana, F.J. Pérez-Cano, O. Castañer, R. Solà, S. Fernandez-Castillejo, Effect of virgin olive oil and thyme phenolic compounds on blood lipid profile: Implications of human gut microbiota, European journal of nutrition 56(1) (2017) 119-131.
66. F. Fatemi, E. Sadroddiny, A. Gheibi, T. Mohammadi Farsani, G.A. Kardar, Biomolecular markers in assessment and treatment of asthma, Respirology 19(4) (2014) 514-523.
67. J. Abolghasemi, M.H. Sharifi, K. Nasiri, A. Akbari, Thyme oxymel by improving of inflammation, oxidative stress, dyslipidemia and homeostasis of some trace elements ameliorates obesity induced by high-fructose/fat diet in male rat, Biomedicine & Pharmacotherapy 126 (2020) 110079.
68. N. Gavaric, S.S. Mozina, N. Kladar, B. Bozin, Chemical profile, antioxidant and antibacterial activity of thyme and oregano essential oils, thymol and carvacrol and their possible synergism, Journal of essential Oil Bearing plants 18(4) (2015) 1013-1021.
69. L. Wan, D. Meng, H. Wang, S. Wan, S. Jiang, S. Huang, L. Wei, P. Yu, Preventive and therapeutic effects of thymol in a lipopolysaccharide-induced acute lung injury mice model, Inflammation 41(1) (2018) 183-192.
70. E.S.M. El-Sayed, A.M. Mansour, M.S. Abdul-Hameed, Thymol and carvacrol prevent doxorubicin-induced cardiotoxicity by abrogation of oxidative stress, inflammation, and apoptosis in rats, Journal of biochemical and molecular toxicology 30(1) (2016) 37-44.
71. E. Zhou, Y. Fu, Z. Wei, Y. Yu, X. Zhang, Z. Yang, Thymol attenuates allergic airway inflammation in ovalbumin (OVA)-induced mouse asthma, Fitoterapia 96 (2014) 131-137.
72. A.M. Mousa, A. Almatroudi, A.S. Alwashmi, W. Al Abdulmonem, A.S. Aljohani, F.A. Alhumaydhi, M.A. Alsahli, F. Alrumaihi, K.S. Allemailem, A.A. Abdellatif, Thyme oil alleviates Ova-induced bronchial asthma through modulating Th2 cytokines, IgE, TSLP and ROS, Biomedicine & Pharmacotherapy 140 (2021) 111726.
73. J. Shao, Z. Yin, Y. Wang, Y. Yang, Q. Tang, M. Zhang, J. Jiao, C. Liu, M. Yang, L. Zhen, Effects of different doses of Eucalyptus oil from Eucalyptus globulus Labill on respiratory tract immunity and immune function in healthy Rats, Frontiers in Pharmacology 11 (2020) 1287.
74. M.H. Kim, S.J. Park, W.M. Yang, Inhalation of Essential Oil from Mentha piperita Ameliorates PM10-Exposed Asthma by Targeting IL-6/JAK2/STAT3 Pathway Based on a Network Pharmacological Analysis, Pharmaceuticals 14(1) (2021) 2.
75. C. Morton, J. Garioch, P. Todd, P. Lamey, A. Forsyth, Contact sensitivity to menthol and peppermint in patients with intra-oral symptoms, Contact Dermatitis 32(5) (1995) 281-284.

76. A.M. Szema, T. Barnett, Allergic reaction to mint leads to asthma, Allergy & rhinology 2(1) (2011) ar. 2011.2. 0008.
77. J. Peng, J. Ma, L. Zhang, B. Lu, Coenzyme Q10 attenuates airway inflammation and oxidative stress in neonatal asthmatic rats, Tropical Journal of Pharmaceutical Research 19(9) (2020) 1969-1975.
78. M. Somayajulu-Nițu, J.K. Sandhu, J. Cohen, M. Sikorska, T. Sridhar, A. Matei, H. Borowy-Borowski, S. Pandey, Paraquat induces oxidative stress, neuronal loss in substantia nigra region and parkinsonism in adult rats: neuroprotection and amelioration of symptoms by water-soluble formulation of coenzyme Q10, BMC neuroscience 10(1) (2009) 1-12.
79. N. Misso, J. Brooks-Wildhaber, S. Ray, H. Vally, P. Thompson, Plasma concentrations of dietary and nondietary antioxidants are low in severe asthma, European Respiratory Journal 26(2) (2005) 257-264.
80. Kumar, S. (2022). A quest for sustainium (sustainability Premium): review of sustainable bonds. Academy of Accounting and Financial Studies Journal, Vol. 26, no.2, pp. 1-18
81. Allugunti, V.R. (2019). Diabetes Kaggle Dataset Adequacy Scrutiny using Factor Exploration and Correlation. International Journal of Recent Technology and Engineering, Volume-8, Issue-1S4, pp 1105-1110.
82. Viswanatha KKRC, Reddy A, Elango N M (2019). Diabetes Kaggle Dataset Adequacy Scrutiny using Factor Exploration and Correlation, International Journal of Recent Technology and Engineering (IJRTE) Vol. 8.
83. F. Gazdik, A. Gvozdjakova, R. Nadvornikova, L. Repicka, E. Jahnova, J. Kucharska, M. Pijak, K. Gazdikova, Decreased levels of coenzyme Q10 in patients with bronchial asthma, Allergy 57(9) (2002) 811-814.
84. A.W. Linnane, H. Eastwood, Cellular redox poise modulation; the role of coenzyme Q10, gene and metabolic regulation, Mitochondrion 4(5-6) (2004) 779-789.
85. A. Gvozdjáková, J. Kucharská, M. Bartkovjaková, K. Gazdíková, F. Gazdík, Coenzyme Q_ {10} supplementation reduces corticosteroids dosage in patients with bronchial asthma, Biofactors 25(1-4) (2005) 235-240.
86. Q. Du, W. Meng, S.S. Athari, R. Wang, The effect of Co-Q10 on allergic rhinitis and allergic asthma, Allergy, Asthma & Clinical Immunology 17(1) (2021) 1-11.